IMF Videos Search Content For Healthcare Professional (122) Healthcare Provider (122) Care Partner (75) Patient (74) Series - Any - ASCO/EHA (49) ASH (60) Ask Dr. Durie (16) Black Swan Research Initiative (5) Community Workshops (4) Emerging Therapies (6) Facebook Live (10) Health Equity (2) IMWG (3) Inspirational (3) Living Well with Myeloma (4) Myeloma in a Minute (1) Myeloma Made Simple (3) Patient & Family Webinar (4) Q&A (7) Recent News and Developments (4) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (65) High-Risk Myeloma (42) High-risk Smoldering Myeloma (34) Late Relapse (4–6 Lines of Therapy) (81) MGUS (35) Newly Diagnosed (Pre-Treatment or First Treatment) (64) Smoldering Myeloma (50) Types of Therapy Immunomodulatory drugs (IMiDs) (58) Immunotherapies (CAR T; BiTE, etc.) (93) Monoclonal antibodies (48) Proteasome inhibitors (43) Stem cell transplant (40) Steroids (41) Supportive Care (36) Year Published 2026 (16) 2025 (38) 2024 (58) 2023 (39) 2022 (10) 2021 (7) 2020 (1) 2019 (9) 2018 (2) 2017 (1) 2016 (3) Trusted Voices Dr. Joseph Mikhael (36) Dr. Brian GM Durie (15) Dr. María-Victoria Mateos (6) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (5) Dr. Saad Usmani (3) Dr. Sigurður Kristinsson (3) Dr. Shaji Kumar (2) Dr. Urvi A. Shah (2) Dr. Sagar Lonial (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Multiple Myeloma Transplant: Examining the Intersection of Access, Age and Race January 27, 2023 ASH Are mass spectrometry and next-generation flow useful tests to evaluate minimal residual disease (MRD)? January 19, 2023 Ask Dr. Durie Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1/2 Results from MonumenTAL-1 January 12, 2023 ASH KarMMa2: Efficacy and Safety of Idecabtagene Vicleucel in High Risk Multiple Myeloma Pts with Early Relapse after ASCT January 12, 2023 ASH Once Weekly Selinexor, Carfilzomib and Dexamethasone in Triple Class Refractory Multiple Myeloma January 10, 2023 ASH MGUS and Risk of Chronic Kidney Disease: Results of the Population-Based iStopMM Study January 2, 2023 ASH Circulating Tumor Plasma Cells in the Screened iStopMM Smoldering Multiple Myeloma Cohort January 2, 2023 ASH Clinical Impact of NGF in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess MRD in Newly Diagnosed Multiple Myeloma Pts Receiving Maintenance December 27, 2022 ASH Autoimmune Diseases Are Not Associated with MGUS: Results of the Population-Based iStopMM December 23, 2022 ASH Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma: Post-Hoc Analysis of Sustained Undetectable MRD December 22, 2022 ASH Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: iStopMM Study December 21, 2022 ASH The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma December 21, 2022 ASH Load More
